Clinical Trials
14 trialsNCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06932952 2026-01-16
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V.
Phase 1 Active not recruiting
NCT05174585 2026-01-06
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2 Completed
NCT05642780 2025-10-14
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Klus Pharma Inc.
Phase 2 Active not recruiting
NCT04937153 2025-07-16
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Genmab
Phase 1 Completed
NCT02608385 2025-06-08
Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
University of Chicago
Phase 1 Active not recruiting
NCT04720976 2025-04-11
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Allist Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05176509 2025-01-06
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT03834948 2023-08-22
AO-176 in Multiple Solid Tumor Malignancies
Arch Oncology
Phase 1/2 Completed
NCT03588039 2023-05-19
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Athenex, Inc.
Phase 1 Terminated
NCT03894540 2022-09-13
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
Ipsen
Phase 1 Terminated
NCT04866485 2021-04-29
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Unknown
NCT02132754 2021-01-28
MK-4166-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02987166 2020-12-16
UVA-AM-001
University of Virginia
Phase 1 Completed